CTI BioPharma Corp. (CTIC): Price and Financial Metrics

CTI BioPharma Corp. (CTIC)

Today's Latest Price: $1.05 USD

0.02 (1.94%)

Updated Sep 25 4:00pm

Add CTIC to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 373 in Biotech

See all "A" rated Strong Buy stocks

CTIC Stock Summary

  • CTIC's price/sales ratio is 33.82; that's higher than the P/S ratio of 94.87% of US stocks.
  • As for revenue growth, note that CTIC's revenue has grown -85.92% over the past 12 months; that beats the revenue growth of only 1.44% of US companies in our set.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for CTIC comes in at -69.52% -- higher than that of just 6.39% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Cti Biopharma Corp, a group of peers worth examining would be HTBX, EPZM, VXRT, QUIK, and PSNL.
  • Visit CTIC's SEC page to see the company's official filings. To visit the company's web site, go to www.ctibiopharma.com.
CTIC Daily Price Range
CTIC 52-Week Price Range

CTIC Stock Price Chart Technical Analysis Charts

CTIC Price/Volume Stats

Current price $1.05 52-week high $1.95
Prev. close $1.03 52-week low $0.62
Day low $1.00 Volume 77,276
Day high $1.05 Avg. volume 432,183
50-day MA $1.26 Dividend yield N/A
200-day MA $1.18 Market Cap 77.40M

CTI BioPharma Corp. (CTIC) Company Bio

CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. The company was founded in 1991 and is based in Seattle, Washington.

CTIC Latest News Stream

Event/Time News Detail
Loading, please wait...

CTIC Latest Social Stream

Loading social stream, please wait...

View Full CTIC Social Stream

Latest CTIC News From Around the Web

Below are the latest news stories about Cti Biopharma Corp that investors may wish to consider to help them evaluate CTIC as an investment opportunity.

CTI BioPharma: A Nano Cap With Interesting Prospects

Introduction Shares of CTI BioPharma (CTIC) has surged this year due to the prospect of getting an accelerated approval for its major product pacritinib. Besides this, the company also participated in the quest to fight Covid-19. Here, it initiated the Phase 3 clinical trial, PRE-VENT, which might bring in results...

Tien Duy Vo on Seeking Alpha | September 5, 2020

CTI BioPharma Reports Second Quarter 2020 Financial Results

CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the second quarter and six months ended June 30, 2020.

Yahoo | August 6, 2020

The Daily Biotech Pulse: Aurinia's Kidney Inflammation Drug Filing Accepted For Review, Intuitive Surgical's Q2 Beat

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 21) ABIOMED, Inc. (NASDAQ: ABMD ) Assembly Biosciences Inc (NASDAQ: ASMB ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI ) Catalent Inc (NYSE: CTLT ) CTI BioPharma Corp (NASDAQ: CTIC ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Heat Biologics Inc (NASDAQ: HTBX ) Hologic, Inc. (NASDAQ: HOLX ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc. (NASDAQ: IMMU ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Ligand Pharmaceuticals Inc. (NASDAQ: LGND ) Natera Inc (NASDAQ: NTRA ) Novo Nordisk A/S (NYSE: NVO ) Opko Health Inc. (NASDAQ: OPK )(moved in reaction to an announcement it will offer ...

Benzinga | July 22, 2020

How Many CTI BioPharma Corp. (NASDAQ:CTIC) Shares Do Institutions Own?

A look at the shareholders of CTI BioPharma Corp. (NASDAQ:CTIC) can tell us which group is most powerful. Institutions...

Yahoo | July 17, 2020

3 Coronavirus Penny Stocks With Triple-Digit Upside Potential

Out on the Street, it’s full speed ahead. Despite the chaotic events of 2020, the S&P 500, which is coming off of its best quarter in more than 20 years, is down by only 2% year-to-date. Somewhat remarkably, the market has continued to charge forward as the number of new COVID-19 cases surges. As COVID-19 could be with us in waves for some time, there’s plenty of uncertainty going forward into the second half of the year. Consequently, spotting compelling plays can feel like a fool’s errand, especially given the hefty toll the virus has already taken on companies spanning multiple sectors.Having said that, the Street’s pros argue that the pandemic has actually positioned some names as beneficiaries. Looking specifically at the biotech sector, massive amounts of capital have been pumped ...

Yahoo | July 6, 2020

Read More 'CTIC' Stories Here

CTIC Price Returns

1-mo -7.08%
3-mo -11.02%
6-mo 14.13%
1-year 22.72%
3-year -66.98%
5-year -92.45%
YTD -33.54%
2019 116.44%
2018 -72.76%
2017 -34.63%
2016 -66.67%
2015 -47.88%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7289 seconds.